文献速递主动脉疾病

遗传性主动脉病与胸主动脉腔内介入治疗的国家注册研究见解

National registry insights on genetic aortopathies and thoracic endovascular aortic interventions.
PubMed 文献 · J Vasc Surg · 2024-05-08

基于血管质量倡议(VQI)2010至2023年19,340例胸主动脉腔内修复(TEVAR)患者,304例(1.6%)患遗传性主动脉病(GA)。GA患者围术期死亡率、院内并发症及再干预几率与无GA者相似,但2年再干预率更高(25% vs 13%;校正风险比1.99;95%CI 1.4-2.9;P<.001),5年生存率相似。

要点

  • GA患者占TEVAR的1.6%,以马凡综合征为主(87%)。
  • GA患者围术期死亡、院内并发症及再干预几率与无GA者无显著差异。
  • GA患者2年再干预率更高(25% vs 13%;校正HR 1.99;95%CI 1.4-2.9;P<.001)。

核心结论

  • GA患者TEVAR初期看似安全,院内并发症、再干预及围术期死亡几率与无GA者相似,5年死亡风险相似,但2年再干预率更高。
  • 未来研究应评估TEVAR与推荐开放修复相比的长期耐久性,以权衡GA患者腔内治疗的风险与获益。

研究设计与样本

  • 回顾性队列研究,纳入血管质量倡议(VQI)数据库2010至2023年所有接受TEVAR的患者,共19,340例,其中304例(1.6%)为GA患者。
  • GA组中87%为马凡综合征,9%为Loeys-Dietz综合征,4%为血管型埃勒斯-当洛斯综合征。
  • 采用多变量logistic回归评估GA与术后结局的独立关联,Kaplan-Meier法和多变量Cox回归评估5年生存率和2年再干预。

主要发现

  • GA患者较无GA者更年轻(50岁[四分位距37-72岁] vs 70岁[四分位距61-77岁]),急性夹层(28% vs 18%)、夹层后动脉瘤(48% vs 17%)、有症状表现(50% vs 39%)更常见,退行性动脉瘤(18% vs 47%)和穿透性主动脉溃疡(及壁内血肿)(3% vs 13%)较少(均P<.001)。
  • GA患者既往升主动脉/弓部修复更多(开放56% vs 11%[P<.001];腔内5.6% vs 2.1%[P=.017]),既往降胸主动脉修复更多(开放12% vs 2%[P=.007];腔内8.2% vs 3.6%[P=.011]),既往开放肾下腹主动脉修复更多(5.3% vs 3.2%),但既往腔内肾下腹主动脉修复更少(3.3% vs 5.5%)(均P<.05)。
  • 校正人口学、合并症及疾病特征后,GA患者围术期死亡(4.6% vs 7.0%;校正比值比[aOR] 1.1;95%CI 0.57-1.9;P=.75)、院内并发症(26% vs 23%;aOR 1.24;95%CI 0.92-1.6;P=.14)及院内再干预(13% vs 8.3%;aOR 1.25;95%CI 0.84-1.80;P=.25)几率与无GA者相似。
  • GA患者术后使用血管加压药(33% vs 27%;aOR 1.44;95%CI 1.1-1.9;P=.006)和输血(25% vs 23%;aOR 1.39;95%CI 1.03-1.9;P=.006)的可能性更高。
  • GA患者2年再干预率更高(25% vs 13%;校正风险比1.99;95%CI 1.4-2.9;P<.001),但5年生存率相似(81% vs 74%;校正风险比1.02;95%CI 0.70-1.50;P=.1)。

关键数值与推荐

  • GA患者与无GA者围术期死亡:4.6% vs 7.0%;aOR 1.1;95%CI 0.57-1.9;P=.75。
  • GA患者与无GA者院内并发症:26% vs 23%;aOR 1.24;95%CI 0.92-1.6;P=.14。
  • GA患者与无GA者院内再干预:13% vs 8.3%;aOR 1.25;95%CI 0.84-1.80;P=.25。
  • GA患者与无GA者术后血管加压药:33% vs 27%;aOR 1.44;95%CI 1.1-1.9;P=.006;输血:25% vs 23%;aOR 1.39;95%CI 1.03-1.9;P=.006。
  • GA患者与无GA者2年再干预率:25% vs 13%;校正HR 1.99;95%CI 1.4-2.9;P<.001;5年生存率:81% vs 74%;校正HR 1.02;95%CI 0.70-1.50;P=.1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) in patients with genetic aortopathies (GA) is controversial, given concerns of durability. We describe characteristics and outcomes after TEVAR in patients with GA. METHODS: All patients undergoing TEVAR between 2010 and 2023 in the Vascular Quality Iniatitive were identified and categorized as having a GA or not. Demographics, baseline, and procedural characteristics were compared among groups. Multivariable logistic regression was used to evaluate the independent association of GA with postoperative outcomes. Kaplan-Meier methods and multivariable Cox regression analyses were used to evaluate 5-year survival and 2-year reinterventions. RESULTS: Of 19,340 patients, 304 (1.6%) had GA (87% Marfan syndrome, 9% Loeys-Dietz syndrome, and 4% vascular Ehlers-Danlos syndrome). Compared with patients without GA, patients with GA were younger (50 years [interquartile range, 37-72 years] vs 70 years [interquartile range, 61-77 years]), more often presented with acute dissection (28% vs 18%), postdissection aneurysm (48% vs 17%), had a symptomatic presentation (50% vs 39%), and were less likely to have degenerative aneurysms (18% vs 47%) or penetrating aortic ulcer (and intramural hematoma) (3% vs 13%) (all P < .001). Patients with GA were more likely to have prior repair of the ascending aorta/arch (open, 56% vs 11% [P < .001]; endovascular, 5.6% vs 2.1% [P = .017]) or the descending thoracic aorta (open, 12% vs 2% [P = .007]; endovascular, 8.2% vs 3.6% [P = .011]). No significant differences were found in prior abdominal suprarenal repairs; however, patients with GA had more prior open infrarenal repairs (5.3% vs 3.2%), but fewer prior endovascular infrarenal repairs (3.3% vs 5.5%) (all P < .05). After adjusting for demographics, comorbidities, and disease characteristics, patients with GA had similar odds of perioperative mortality (4.6% vs 7.0%; adjusted odds ratio [aOR], 1.1; 95% confidence interval [CI], 0.57-1.9; P = .75), any in-hospital complication (26% vs 23%; aOR, 1.24; 95% CI, 0.92-1.6; P = .14), or in-hospital reintervention (13% vs 8.3%; aOR, 1.25; 95% CI, 0.84-1.80; P = .25) compared with patients without GA. However, patients with GA had a higher likelihood of postoperative vasopressors (33% vs 27%; aOR, 1.44; 95% CI, 1.1-1.9; P = .006) and transfusion (25% vs 23%; aOR, 1.39; 95% CI, 1.03-1.9; P = .006). The 2-year reintervention rates were higher in patients with GA (25% vs 13%; adjusted hazard ratio, 1.99; 95% CI, 1.4-2.9; P < .001), but 5-year survival was similar (81% vs 74%; adjusted hazard ratio, 1.02; 95% CI, 0.70-1.50; P = .1). CONCLUSIONS: TEVAR for patients with GA seemed to be safe initially, with similar odds for in-hospital complications, in-hospital reinterventions, and perioperative mortality, as well as similar hazards for 5-year mortality compared with patients without GA. However, patients with GA had higher 2-year reintervention rates. Future studies should assess long-term durability after TEVAR compared with the recommended open repair to appropriately weigh the risks and benefits of endovascular treatment in patients with GA.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gomez-Mayorga JL, Yadavalli SD, Allievi S, et al. National registry insights on genetic aortopathies and thoracic endovascular aortic interventions. J Vasc Surg. 2024. PMID: 38729586. doi:10.1016/j.jvs.2024.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。